Key result
Cloud-hosted mechanistic platform predicts drug concentrations, efficacy, and early warning signs of chronic cardiotoxicity.
Why the study?
Directly and precisely measuring drug concentrations in human cardiac tissues is challenging, and target site concentrations may not correlate with plasma levels due to complex physiological factors and variability.
Answers are grounded in this paper and cite their sources.
A novel cloud-hosted mechanistic platform was developed to predict local cardiac drug concentrations and provide early warning signatures for drug-induced cardiotoxicity.
Directly and precisely measuring the drug concentration in human cardiac tissues is challenging in healthy individuals. Due to the interplay of complex physiological factors, inter-individual and intra-individual variability, the drug concentration profiles at target sites in cardiac tissues may not necessarily correlate with drug concentration in plasma. Here, we develop, calibrate, test and evaluate rational mechanistic, interactive, cloud-based platforms to reliably predict the local drug concentrations and useful predictions of drug efficacy and safety in cardiac tissues and target sites. Our safety and efficacy tools are based on building the detailed and precise understanding of drug absorption, binding, distribution and metabolism within cardiac tissues. Through our experiments we screen and identify established drugs/novel molecular entities (NMEs) and concentrations which can induce cardiotoxicity or suboptimal efficacy. We have evaluated and calibrated our cardiac safety platform based on the clinical data for these classes of compounds: (a) anti-cancer molecules; (b) non-steroid anti-inflammatory; (c) beta blockers; (d) cardioactive steroids; (e) anti-dysrhythmic drugs; (f) compounds prolonging the QT interval. Different classes of these compounds and their therapeutic/ administration concentrations may induce distinct cardiovascular toxicity. One of the fundamental tasks of our interactive, simpler, cloud-hosted and easy to use platform is to provide early warning signatures of chronic cardiac toxicities either induced by different medicinal compounds or environmental toxins. Typically, acute poisoning can be identified and linked to the underlying compound or mechanism. However, chronic negative effects may not surface for a long time and early diagnosis of these toxins or drug-drug interactions (DDIs) is challenging. Here based on sensitivity and population tools, we aim to provide a platform for predicting early warning signatures in chronic cardiac toxicities induced either by medicinal compounds or environmental toxins. With our platforms we analyze the mechanisms of cardiotoxicity including the toxicity to the heart and toxicity to the vascular system. In the context of toxicity to the heart we are investigating the mechanisms leading to: (1) rhythm disturbances; (2) myocardial ischemia; (3) left ventricular (LV) dysfunction; (4) drug-induced LV dysfunction; (5) myocarditis; (6) impairment of cardiac volumes; and (7) induction of pericardial disease. Furthermore, the underlying mechanisms of drug-induced toxicity to the vascular systems are also analyzed and toxic effects of drug candidates on arterial blood pressure and drug-induced thromboembolic complications are mapped through our platforms. This abstract was presented at the American Physiology Summit 2026 and is only available in HTML format. There is no downloadable file or PDF version. The Physiology editorial board was not involved in the peer review process.
No takes yet. Share an insight, caveat, or question.
Aslam et al. (2026) studied Cardiotoxicity and drug efficacy. Mechanistic cloud-based platform was evaluated. A mechanistic, cloud-hosted platform was developed and calibrated to predict local drug concentrations, efficacy, and early warning signatures of chronic cardiotoxicity across multiple drug classes.
Synapse has enriched 10 related papers. Consider them for comparative context: